

## References

1. Ehtesham N, Rafie MZ, Mosallaei M. The global prevalence of familial multiple sclerosis: an updated systematic review and meta-analysis. *BMC Neurology*. 2021;21(1):246.
2. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. *Multiple sclerosis* (Houndmills, Basingstoke, England). 2020;26(14):1816-1821.
3. Pozzilli C. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. *Expert review of neurotherapeutics*. 2013;13(12 Suppl):49-54.
4. Pozzilli C. Overview of MS Spasticity. *European Neurology*. 2014;71(Suppl. 1):1-3.
5. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses. 2001; [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp). Accessed Aug 22, 2022.
6. JBI. Critical appraisal tools: Checklist for analytical cross-sectional studies. 2022; <https://jbi.global/critical-appraisal-tools>. Accessed August 22, 2022
7. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009;339:b2535.
8. Gustavsen SO, A.;Sondergaard, H. B.;Andresen, S. R.;Sorensen, P. S.;Sellebjerg, F.;Oturai, A. The association of selected multiple sclerosis symptoms with disability and quality of life: a large Danish self-report survey. *BMC Neurology*. 2021;21(1) (no pagination)(317).
9. Oreja-Guevara CG-S, D.;Vila, C. Spasticity in multiple sclerosis: Results of a patient survey. *International Journal of Neuroscience*. 2013;123(6):400-408.
10. Rommer PSE, K.;Ellenberger, D.;Flachenecker, P.;Friede, T.;Haas, J.;Kleinschnitz, C.;Pohlau, D.;Rienhoff, O.;Stahmann, A.;Zettl, U. K. Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry. *Multiple Sclerosis Journal*. 2019;25(12):1641-1652.
11. Skierlo SR, P. S.;Zettl, U. K. Symptomatic treatment in multiple sclerosis-interim analysis of a nationwide registry. *Acta Neurologica Scandinavica*. 2017;135(4):394-399.
12. Rizzo MAH, O. C.;Preiningerova, J.;Vollmer, T. L. Prevalence and treatment of spasticity reported by multiple sclerosis patients. *Multiple Sclerosis*. 2004;10(5):589-595.
13. Arroyo RM, M.;Vila, C. Correlation between spasticity and quality of life in patients with multiple sclerosis: The CANDLE study. *International Journal of Neuroscience*. 2013;123(12):850-858.
14. Hendin. Variability of Spasticity in Multiple Sclerosis – Results from SEEN-MSS, a Large-Scale, Self-Reported Survey. 2022; <https://cmssc.confex.com/cmssc/2022/meetingapp.cgi/Paper/7929> . Accessed August 8, 2022.
15. EuroQoL Research Foundation. EXPLAINING THE EQ-5D IN ABOUT TWO-AND-A-HALF-MINUTES. 2022; <https://euroqol.org/eq-5d-instruments/>. Accessed December 17, 2022.
16. Barin LS, A.;Disanto, G.;Babacic, H.;Calabrese, P.;Chan, A.;Kamm, C. P.;Kesselring, J.;Kuhle, J.;Gobbi, C.;Pot, C.;Puhan, M. A.;von Wyl, V. The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most? *Multiple Sclerosis and Related Disorders*. 2018;25:112-121.
17. Flachenecker PH, T.;Zettl, U. K. Spasticity in patients with multiple sclerosis - clinical characteristics, treatment and quality of life. *Acta Neurologica Scandinavica*. 2013.
18. Svensson JB, S.;Nilsson, P. Costs and quality of life in multiple sclerosis patients with spasticity. *Acta Neurologica Scandinavica*. 2014;129(1):13-20.

19. Vermersch P. MObility ImproVEment with spasticity in multiple sclerosis in Europe: The MOVE 1 EU study. *Neurodegenerative Disease Management*. 2014;4(6):407-415.20.
20. D'Hooghe MW, B.;Delvaux, V.;D'Haeseleer, M.;Guillaume, D.;Laureys, G.;Nagels, G.;Vanderdonckt, P.;Van Pesch, V.;Popescu, V. Sativex (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience. *BMC Neurology*. 2021;21(1) (no pagination)(227).
21. Vermersch PT, M. Tetrahydrocannabinol: Cannabidiol oromucosal spray for multiple sclerosis-related resistant spasticity in daily practice. *European Neurology*. 2016;76(5-6):216-226.
22. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation*. 1995;4(3):187-206.
23. Meca-Lallana JEB, J. J.;Lacruz, F.;Guijarro, C.;Sanchez, O.;Cano, A.;Costa-Frossard, L.;Hernandez-Clares, R.;Sanchez-De La Rosa, R. Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-beta to glatiramer acetate: The Escala Study. *Journal of the Neurological Sciences*. 2012;315(1-2):123-128.
24. Edemekong PF, Bomgaars DL, Sukumaran S, Schoo C. Activities of Daily Living. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
25. Elite Learning. The (Original) Barthel Index of ADLs. 2022; <https://www.elitelearning.com/resource-center/rehabilitation-therapy/the-original-barthel-index-of-adls/>. Accessed December 17, 2022.
26. Frechin JM. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: A retrospective, observational study. *Neurodegenerative Disease Management*. 2018;8(3):151-159.
27. Paul FS, C. V. Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity. *Neurodegenerative Disease Management*. 2021;11(2):143-153.
28. Jarrett LN, P.;Thompson, A. J. Managing severe lower limb spasticity in multiple sclerosis: Does intrathecal phenol have a role? *Journal of Neurology Neurosurgery and Psychiatry*. 2002;73(6):705-709.
29. Bethoux FM, R. A. A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis. *Patient*. 2016;9(6):537-546.
30. Zettl UKH, T.;Essner, U.;Flachenecker, P. Burden of disease in multiple sclerosis patients with spasticity in Germany: Mobility improvement study (Move I). *European Journal of Health Economics*. 2014;15(9):953-966.
31. Arroyo RV, C.;Clissold, S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the '5E' study. *Expert rev*. 2011;11(2):205-213.
32. Stevenson VLG, A.;Bardos, J. I.;Broughton, J. The high cost of spasticity in multiple sclerosis to individuals and society. *Multiple Sclerosis*. 2015;21(12):1583-1592.